Even though it still awaits a substantial venture capital investment for mass implementation, is Dr. Anita Goel’s Gene RADAR the future of instant medical diagnosis for the world’s poor?
By: Ringo Bones
Even though her invention is a 500,000 US dollar XPRIZE Foundation Challenge winner, Dr. Anita Goel’s Gene RADAR still awaits substantial venture capital investment for it to begin benefitting the medical diagnostic cost burden to those over a billion people around the world who earns less than 2 US dollars a day. Current reliable medical diagnostic tests to find out if whether someone has HIV / AIDS, the dreaded Ebola virus or just your garden variety flu used to take about a month for results, while the upcoming Gene RADAR was recently demonstrated to accurately do the same feat within an hour using just a drop of blood from the patient.
Dr. Anita Goel received a Ph.D. in physics from Harvard University and is globally recognized for her pioneering research in nano-biophysics particularly for the study of molecular mechanisms behind the reading and writing information in DNA. Currently the chairwoman and CEO of Nanobiosym Diagnostics, the Harvard-M.I.T. trained physicist and physician now eagerly awaits for substantial venture capitalist investment to make her Gene RADAR a commercially viable product that could benefit patients who earn less than 2 US dollars a day.
The nanotechnology platform based Gene RADAR developed by Nanobiosym Diagnostics is the first medical diagnostic tool of its kind that is not only as accurate and reliable as existing medical diagnostic lab equipment used in testing HIV / AIDS, Ebola and the flu, but can also produce reliable results within an hour at a fraction of the costs of current similar medical diagnostic tools. When deployed in Ebola hot-spots in the near future, Gene RADAR could make the 2014 West African Ebola Pandemic a thing of the past.